Smart Library
Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.
New to hirudotherapy? Start here
This library indexes the full evidence base. For orientation, begin with the core guides:
Filters
Evidence level
Showing 9 of 755 entries. Refine via URL query params.
Compounds
9Bivalirudin
Synthetic 20-amino-acid hirudin analog — FDA-approved direct thrombin inhibitor for PCI anticoagulation ($636M peak revenue).
Lepirudin
First-generation recombinant hirudin — FDA-approved 1998 for heparin-induced thrombocytopenia (HIT). Withdrawn 2012 by Bayer for commercial reasons.
Desirudin
Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.
Dabigatran
Oral direct thrombin inhibitor — FDA approved 2010 for stroke prevention in atrial fibrillation. Synthetic; designed from the inhibitor NAPAP, not derived from hirudin.
Argatroban
Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT, later also for PCI in patients with or at risk of HIT. Derived from arginine, not from hirudin.
Rivaroxaban
Oral Factor Xa inhibitor — FDA approved 2011. Synthetic (Bayer, oxazolidinone series); shares its target with the leech protein antistasin but is not derived from it.
Apixaban
Oral Factor Xa inhibitor — FDA approved 2012. Synthetic; shares its target with the leech protein antistasin but is not derived from it.
Edoxaban
Oral Factor Xa inhibitor — FDA approved 2015. Synthetic; shares its target with the leech protein antistasin but is not derived from it.
Eptifibatide
Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.